Explore the vast range of titles available.

In Italy, health care is free and considered to be of a good standard, but this does not mean that barriers to treatment do not exist. Here, Mapelli discusses the difficulty in accessing to care experienced by a patient with advanced heart failure.

A pandemic by a novel coronavirus disease (COVID‐19) has been declared by the World Health Organization. Lombardy, the region of our tertiary referral centre for heart diseases in Northern Italy, has been particularly hit by the pandemic. According to the government's prescriptions, all elective activities and procedures in the last months were suspended in order to concentrate our efforts on COVID‐19 patients' care. Entire departments have been turned into ‘COVID‐19 units’, where healthcare professionals are daily involved in supporting critically ill patients. On a personal level, this was a period of special feelings and peculiar unexpected events. People close to healthcare workers have been affected, and our lives have been turned upside down. Furthermore, right in this period, few colleagues (and friends) are facing entirely new events in their lives, such as fatherhood with its load of joy and concern. Through the case of a young woman recently admitted to our department with a severe heart failure due to a peripartum cardiomyopathy, described in narrative form, this manuscript would help all those involved in the front line in the fight against the pandemic in these difficult times.

Pediatric cardiology remains a fascinating yet challenging niche within medicine [...]

ObjectivesIron deficiency (ID) is frequent in heart failure (HF). Among patients with HF and ID, those with impaired iron transport (IIT) (transferrin saturation (TSAT) <20%) have the worst ID phenotype. In HF, exercise limitation is mainly related to abnormality in oxygen delivery (VO2) and utilisation and/or to ventilation inefficiency. We evaluated whether it is possible to identify the leading cause of exercise limitation in patients with HF and IIT.DesignObservational study.SettingRetrospective study.ParticipantsWe analysed 1043 consecutive hospitalised patients with HF (66±14 years, 49.8% females) who underwent cardiopulmonary exercise test (CPET).Outcome measuresAssociations between CPET parameters and TSAT were explored using general linear models adjusted for potential confounders (haemoglobin, left ventricle ejection fraction, age, gender, C reactive protein, serum creatinine).ResultsWe observed that: (a) 413 patients with HF and IIT had worse functional capacity compared with non-IIT cases: peak VO2 (15±3 vs 16±6 mL/min/kg, p<0.0001) and ventilation/carbon dioxide relationship (VE/VCO2) slope (38±9 vs 33±8, p<0.0001); (b) VE/VCO2 values remained significantly different between IIT and non-IIT cases after adjusting for confounding variables including peak VO2; differently, peak VO2 after adjusting also for VE/VCO2 slope, resulted not different in IIT compared with non-IIT HF cases; (c) patients with both low peak VO2 (<14 mL/min/kg) and high VE/VCO2 (≥34) had a higher B-type natriuretic peptide (BNP), lower TSAT and higher MECKI (Metabolic Exercise combined with Cardiac and Kidney Index) score compared with patients with high peak VO2 and low VE/VCO2 (BNP 951±1041 vs 413±623 pg/mL (p<0.0001); TSAT 19.5%±10.5% vs 26.9%±10.2% (p<0.0001); MECKI score 14.8%±1.4% vs 1.2%±2.3% (p<0.0001).ConclusionsHigh VE/VCO2 slope is directly associated with IIT, independent of peak VO2, suggesting a pivotal role for ventilation inefficiency in exercise impairment in patients with IIT and HF. In patients with HF, the worst exercise performance is associated with low TSAT, high BNP and the highest MECKI score.

Background: Cardiopulmonary exercise testing (CPET) is increasingly recognized as a key tool for evaluating patients with congenital heart disease (CHD). While traditional assessments focus on resting parameters, CPET provides dynamic, integrated insight into cardiovascular, respiratory, and muscular function during exertion. Objectives: This review explores the clinical value of CPET across the spectrum of CHD, with dedicated focus on its applications in both adult and paediatric populations. We analyse the prognostic significance of key CPET parameters—particularly peak oxygen consumption (peak VO2), ventilatory efficiency (VE/VCO2 slope), and heart rate dynamics—within distinct anatomical and physiological categories of CHD. Findings: CPET reliably detects exercise intolerance, guides intervention timing, informs exercise prescription, and stratifies risk. Peak VO2 and heart rate reserve are consistently associated with adverse outcomes across most CHD types. However, the prognostic utility of other variables, such as the VE/VCO2 slope, varies with pathophysiology—being less reliable in cyanotic lesions like Eisenmenger syndrome. In paediatric patients, CPET must be adapted to growth-related physiological variability and is increasingly used to assess quality of life, functional limitation, and response to therapy. Conclusions: CPET is a powerful, non-invasive tool that should be integrated into routine management of CHD patients across all ages. It enhances risk assessment, supports tailored care, and promotes safe physical activity, ultimately contributing to improved long-term outcomes and quality of life.

BackgroundPulmonary embolism (PE) has been described in coronavirus disease 2019 (COVID-19) critically ill patients, but the evidence from more heterogeneous cohorts is limited.MethodsData were retrospectively obtained from consecutive COVID-19 patients admitted to 13 Cardiology Units in Italy, from March 1st to April 9th, 2020, and followed until in-hospital death, discharge, or April 23rd, 2020. The association of baseline variables with computed tomography-confirmed PE was investigated by Cox hazards regression analysis. The relationship between d-dimer levels and PE incidence was evaluated using restricted cubic splines models.ResultsThe study included 689 patients (67.3 ± 13.2 year-old, 69.4% males), of whom 43.6% were non-invasively ventilated and 15.8% invasively. 52 (7.5%) had PE over 15 (9–24) days of follow-up. Compared with those without PE, these subjects had younger age, higher BMI, less often heart failure and chronic kidney disease, more severe cardio-pulmonary involvement, and higher admission d-dimer [4344 (1099–15,118) vs. 818.5 (417–1460) ng/mL, p < 0.001]. They also received more frequently darunavir/ritonavir, tocilizumab and ventilation support. Furthermore, they faced more bleeding episodes requiring transfusion (15.6% vs. 5.1%, p < 0.001) and non-significantly higher in-hospital mortality (34.6% vs. 22.9%, p = 0.06). In multivariate regression, only d-dimer was associated with PE (HR 1.72, 95% CI 1.13–2.62; p = 0.01). The relation between d-dimer concentrations and PE incidence was linear, without inflection point. Only two subjects had a baseline d-dimer < 500 ng/mL.ConclusionsPE occurs in a sizable proportion of hospitalized COVID-19 patients. The implications of bleeding events and the role of d-dimer in this population need to be clarified.Graphic abstract

The first time we met was in the pediatric ward of St [...]

Nasal and oral exclusive breathing modes have benefits and drawbacks during submaximal exercise. It is less known whether these responses would extend to anaerobic work performed at high intensity. The purpose of this study is to find the most efficient mode of breathing during different phases of a maximal exercise at cardiopulmonary exercise test (CPET). Healthy subjects were recruited to perform 4 maximal CPETs (standard conditions (STD), exclusively nasal breathing (eNAS), exclusively oral breathing (eOR), partial nasal breathing (pNAS) with just one blocked nostril) using the same ramp protocol on an electronically braked cycle ergometer. Before the exercise a standard spirometry was executed in the same order. Twelve healthy subjects (28.6 ± 5.2 y, 50% males) performed the 4 CPETs within one month. Variables were analysed at rest, at anaerobic threshold (AT), at intermediate exercise steps, and at peak. Compared to STD, eOR, and pNAS conditions, eNAS was associated with a significant lower peakVO2, peakVCO2, peak ventilation, respiratory rate, VE/VCO2 slope, respiratory exchange ratio, and workload (p < 0.05 for all). Moreover, peak inspiration and peak expiration time were augmented, while forced expiratory volume and vital capacity at rest were reduced. Only minor differences were detected at rest or AT. eNAS breathing Borg scale was higher in all phases of the exercise. In young healthy subjects, an exclusively nasal respiration induces significant impairment on peak exercise capacity at CPET due to ventilatory limitation, with only minor effects on metabolic parameters at rest and in submaximal effort.

Background: Sodium/glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin and empagliflozin, are currently a standard therapy for heart failure (HF) patients. We report the real-world use of SGLT2is in a monocentric cohort of HF patients with reduced ejection fraction (HFrEF) and improved ejection fraction (HFimpEF), comparing patient characteristics and outcomes with those observed in large-scale randomized clinical trials (RCTs). Methods: We retrospectively analyzed a cohort of 370 stable patients with HFrEF or HFimpEF who initiated therapy with dapagliflozin or empagliflozin between June 2019 and November 2023. Baseline data, including medical history, concomitant diseases, therapy, laboratory tests, echocardiographic results and cardiopulmonary exercise tests (CPETs), were collected at the start of the therapy with SGLT2is. After a median period of 18 months, follow-up data on treatment adherence, adverse events, hospitalizations, and mortality were also reviewed. A comparison was made between patients taking dapagliflozin and those taking empagliflozin and then individual populations were compared with those from the trials. Results: Among 370 patients (81% HFrEF, 19% HFimpEF), 276 received dapagliflozin and 94 empagliflozin. Empagliflozin patients were older, had higher NYHA class and LVEF, and higher incidence of diabetes, while dapagliflozin users had greater use of sacubitril/valsartan and mineralocorticoid receptor antagonists. Both groups were older than the RCT cohorts. Dapagliflozin patients had LVEF comparable to DAPA-HF, while empagliflozin patients had higher LVEF than EMPEROR-Reduced. HF hospitalizations were more frequent in the real-world groups, but mortality was lower than in RCTs. The composite outcome of death and worsening HF was higher in the real-world dapagliflozin cohort vs. DAPA-HF but similar between the real-world empagliflozin cohort and EMPEROR-Reduced. Conclusions: In this real-world cohort, the use of empagliflozin was associated with cardio-nephro-metabolic comorbidities and dapagliflozin being prescribed more frequently for patients with isolated cardiac symptoms. While outcomes were generally favorable, they differed from those seen in RCTs, highlighting the importance of real-world data in understanding the practical application of these therapies.